Fig. 6

Pharmacokinetic profiles of 4D5scFv-WT, 4D5scFv-G125-HSA, and 4D5scFv-G178-HSA. Samples were injected into BALB/c mice (n = 5). Anti-HER2 ELISA analysis of the residual 4D5scFv-WT and 4D5scFv-HSA conjugates were measured at different time points (4D5scFv-WT; 5 min, 1 h and 4D5scFv-HSA conjugates; 5 min, 2, 4, 8, 12, 24, 36, and 48 h). α-phase and β-phase indicate the serum half-lives in the early phase (0 to 8 h) and late phase (8 to 48 h), respectively